Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07111546) titled 'A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Nanjing Leads Biolabs Co.,Ltd
Condition:
Advanced Solid Tumour
Intervention:
Drug: LBL-024 for Injection
Drug: Durvalumab Injection
Drug: Cisplatin Injection
Drug: Gemcitabine Hydrochloride for Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 26, 2025
Target Sample ...